Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30764735 | 0.85 | HSD11B1 (0.51) | HSD11B1ATMGFERALDH1A1HTT | |
| SCHEMBL30764758 | 0.84 | KDM4E (0.59) | HSD11B1ATMGFERALDH1A1SMN1; SMN2 | |
| SCHEMBL30764755 | 0.83 | GAA (0.54) | HSD11B1ALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL30764715 | 0.82 | HSD11B1 (0.51) | HSD11B1ATMGFERMEN1KMT2A | |
| SCHEMBL13149275 | 0.82 | ALDH1A1 (0.77) | HSD11B1ATMGFERALDH1A1LMNA | |
| SCHEMBL30764749 | 0.80 | HSD11B1 (0.49) | HSD11B1ATMGFERMEN1KMT2A | |
| SCHEMBL30764718 | 0.80 | HSD11B1 (0.49) | HSD11B1ATMGFERALDH1A1LMNA | |
| SCHEMBL30764717 | 0.80 | HSD11B1 (0.46) | HSD11B1ATMGFERALDH1A1LMNA | |
| SCHEMBL27253355 | 0.79 | HSD11B1 (0.62) | HSD11B1ATMGFERALDH1A1LMNA | |
| SCHEMBL30764713 | 0.78 | HSD11B1 (0.47) | HSD11B1ATMGFERALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | HSD11B1 32/4885ATM 4122/4885GFER 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.